KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average: 2018-2025

Historic Equity Average for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Sep 2025 value amounting to -$111.2 million.

  • Amneal Pharmaceuticals' Equity Average fell 47.29% to -$111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.2 million, marking a year-over-year decrease of 47.29%. This contributed to the annual value of -$44.8 million for FY2024, which is 143.88% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Equity Average stood at -$111.2 million, which was up 9.02% from -$122.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Equity Average's 5-year high stood at $387.2 million during Q1 2022, with a 5-year trough of -$122.3 million in Q2 2025.
  • Over the past 3 years, Amneal Pharmaceuticals' median Equity Average value was -$60.6 million (recorded in 2024), while the average stood at -$6.5 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Equity Average climbed by 8.82% in 2022, and later crashed by 453.70% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Equity Average stood at $375.1 million in 2021, then crashed by 49.57% to $189.1 million in 2022, then plummeted by 53.94% to $87.1 million in 2023, then tumbled by 216.55% to -$101.5 million in 2024, then crashed by 47.29% to -$111.2 million in 2025.
  • Its Equity Average stands at -$111.2 million for Q3 2025, versus -$122.3 million for Q2 2025 and -$120.8 million for Q1 2025.